Absolute benefit and relative benefit

Category: Evidence · Editorial Review: Updated 20 October 2026 · 3 minute read

Two ways to describe a difference

Relative benefit compares an outcome proportionally with another group. Absolute benefit describes the difference in actual event rates or outcomes. Both can be useful, but a large relative change can correspond to a small absolute change when the starting risk is low. Patients should ask for the underlying numbers rather than relying on a headline percentage.

Use a clearly labeled illustration

Imagine a hypothetical study in which an outcome occurs in 10 of 100 people in one group and 15 of 100 in another. The absolute difference is 5 people per 100. The relative increase is 50 percent. These describe the same result but create different impressions. This example is arithmetic, not an estimate for any stem cell treatment.

Ask who is in the denominator

A reported success rate may count only patients who completed follow-up or only those selected for a particular analysis. It may exclude people who stopped treatment or did not respond to a survey. Ask how many people began treatment, how many were assessed, and how success was defined. Without those details, a percentage is difficult to evaluate.

Bring the number back to your decision

Ask whether study participants resemble you and whether the measured benefit is worth the burdens and risks in your situation. An average result does not predict an individual response. A useful consultation explains the likely range of outcomes and the uncertainty around the estimate rather than presenting a single percentage as a personal guarantee.

Continue exploring

• Preclinical research: before a treatment reaches people
• Blinding and placebo effects
• Clinical endpoints: what counts as improvement
• Prepare your consultation checklist

Sources & further reading

• National Cancer Institute — How Clinical Trials Work
• ISSCR — Guide to Stem Cell Treatments

Read alongside your treating specialist’s advice. Clinical eligibility, exact products and treatment plans require individual assessment.